Racura OncologyASX:RAC -5.96%31 PB Ratio is 17.00 as of Jun. 26, 2026. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 1,232 Biotechnology companies, Racura Oncology ranks worse than 92.69% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Racura Oncology's share price is A$2.21. Racura Oncology's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.13. Hence, Racura Oncology's PB Ratio of today is 17.00.
The historical rank and industry rank for Racura Oncology's PB Ratio or its related term are showing as below:
ASX:RAC'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 18.69
Current: 17
During the past 10 years, Racura Oncology's highest PB Ratio was 18.69. The lowest was 0.00. And the median was 0.00.
ASX:RAC's PB Ratio is ranked worse than 92.69% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ASX:RAC: 17.00
During the past 12 months, Racura Oncology's average Book Value Per Share Growth Rate was -14.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Racura Oncology was 54.70% per year. The lowest was -27.60% per year. And the median was -2.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Racura Oncology PB Ratio Related Terms
Racura Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Racura Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Racura Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Racura Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Racura Oncology's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Racura Oncology (ASX:RAC) has a PB Ratio of 17.00 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #1142 out of 1232 companies in the Biotechnology industry, placing it in the top 92.7%.
Is Racura Oncology's PB Ratio too high?
Racura Oncology's current PB Ratio is 17.00. The Biotechnology industry median PB Ratio is 2.80. Racura Oncology's value of 17.00 is 507.1% above this industry median. Based on the distribution chart, Racura Oncology ranks #1142 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #1142 out of 1232 companies for PB Ratio. This places Racura Oncology in the lower half of its industry. The industry median PB Ratio is 2.80. Racura Oncology's value of 17.00 is 507.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Racura Oncology's current PB Ratio of 17.00 is 507.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Racura Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current PB Ratio is 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current PB Ratio of 17.00. The current PB Ratio is 17.00 and 507.1% above the Biotechnology industry median of 2.80. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current PB Ratio is 17.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score
Get the complete analysis for ASX:RAC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
